bf/NASDAQ:OCGN_icon.jpeg

NASDAQ:OCGN

Ocugen, Inc.

  • Stock

USD

Last Close

1.38

06/11 22:32

Market Cap

465.81M

Beta: 3.71

Volume Today

2.59M

Avg: 6.32M

PE Ratio

−1.82

PFCF: −1.70

    Description

    Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis...Show More

    Earnings

    Earnings per Share (Estimate*)

    -4-2242019-05-152021-05-072023-05-052024-02-272024-11-08

    Revenue (Estimate*)

    20M40M60M80M2019-05-152021-05-072023-05-052024-02-272024-11-08

    *Estimate based on analyst consensus